“There are currently no effective solutions to treat age-related decline in muscle function other than months of exercise. This is an important first clinical validation that shows Urolithin A could be a promising solution for the management of healthy muscle function during ageing,” says Professor Roger Fielding, PhD of Tufts University.
“This positive clinical translation of Urolithin A shows its potential to play an important role in advanced nutritional approaches to improve mitochondrial health through mitophagy and biogenesis, and, as a result, cellular health in humans,” says co-author Professor Johan Auwerx, MD, PhD of Amazentis Ecole Polytechnique Fédérale de Lausanne.
As published in the journal Nature Metabolism 60 healthy but sedentary elderly participants were divided into 4 groups received either a placebo, 250, 500, or 1,000 mg dose of Urolithin A daily over the course of 28 days. Efficacy of UA was determined by examining cellular and mitochondrial health biomarkers in blood and muscle tissue; findings suggest that Urolithin A may help to slow down the aging process by improving the functioning of the mitochondria.
Urolithin A may be the only known compound that can re-establish a cell’s ability to recycle defective mitochondria, this happens naturally in younger people but with age the body loses it ability to do this causing sarcopenia and weakening of other tissues.
Urolithin A is a microflora derived metabolite of ellagitannins, and it is the lead candidate of Amazentis as an oral formulation, the company hopes to build on the promising results to bring a product to market quickly. Nestle Health Science has announced a global partnership with the company to develop products containing UA to develop opportunities in healthcare and medical nutrition.
